For the roughly seven million Americans living with Alzheimer’s, the newest treatments have come with a heavy logistical price: an intravenous infusion at a hospital or clinic every two weeks, indefinitely. Now US regulators have approved a way to start one of those drugs at home instead – a once-weekly injection that takes about 15 seconds.
The decision clears a subcutaneous starter dose of lecanemab, sold as Leqembi IQLIK, making it the first anti-amyloid Alzheimer’s drug that can be both begun and given away from an infusion chair. It is a genuine step toward a more practical at-home Alzheimer’s treatment – though, importantly, the change is about convenience and access, not about the drug working any better.
That distinction matters, because the anti-amyloid drugs remain among the most debated in modern medicine. Their benefits are modest, their risks are real, and their arrival at the bedside is unfolding alongside an equally important shift in how the disease is diagnosed in the first place.
What Just Changed
Until now, patients starting lecanemab faced infusions every fortnight, each requiring a trip to a hospital or dedicated infusion centre. The new approval lets them begin with a weekly shot under the skin instead: 500 mg given as two 250 mg injections, each lasting about 15 seconds, delivered with an autoinjector of the kind already familiar from diabetes, arthritis and severe-allergy treatments.
Crucially, it can be done at home, by the patient or a caregiver. An earlier 2025 approval had allowed subcutaneous dosing only for people who had already completed 18 months of intravenous treatment; this goes further, permitting the at-home injection from day one. People with early Alzheimer’s can now choose how to start – weekly injections or the traditional infusions – rather than being funnelled into the clinic.
Why At-Home Delivery Matters
The value here is measured in time, distance and dignity. For someone with early cognitive decline, a fortnightly hospital visit is not a small thing: it can mean arranging transport, taking a carer away from work, and spending hours in a clinical setting, over and over. For those in rural areas or far from an infusion centre, it can be the difference between getting the drug and going without.
The Alzheimer’s Association welcomed the move on exactly those grounds. “This FDA action demonstrates the continued progress of anti-amyloid treatments for Alzheimer’s disease,” the organisation said, noting that for people who face transportation, mobility or scheduling challenges, an injection at home offers another route to treatment. It is the same logic reshaping other therapies – the shift from clinic to kitchen table that also drove the arrival of an oral weight-loss pill this year: a treatment only helps if people can realistically take it.
How Well the Drugs Actually Work
None of this would matter if the drug did nothing, and here the picture calls for honesty. Lecanemab and its cousin donanemab are the first treatments shown to alter the course of Alzheimer’s rather than merely ease symptoms, by clearing the sticky amyloid plaques that build up in the brain. But the effect is measured in slowing, not stopping.
In their pivotal trials, lecanemab slowed the decline of early Alzheimer’s by roughly 27% and donanemab by about 35% over 18 months, compared with placebo. In practice that can translate into several extra months of preserved function – meaningful to a family, but far from a cure. These are drugs for early, amyloid-confirmed disease, not a rescue for advanced dementia, and the benefit is real but incremental.
It helps to understand what the drugs are doing. Alzheimer’s is marked by a build-up of a protein called amyloid-beta, which clumps into plaques between brain cells years before memory problems appear. Lecanemab and donanemab are antibodies engineered to latch onto that amyloid and prompt the immune system to clear it. Removing the plaques appears to slow the damage, but it does not repair what has already been lost – which is why starting early, while decline is still mild, matters so much to how well they work.
The Debate Over the Evidence
Just how meaningful that benefit is remains genuinely contested. In April 2026, a Cochrane systematic review pooled 17 trials and more than 20,000 participants across the whole anti-amyloid antibody class and concluded the drugs “probably result in little to no difference” in cognitive function – a stark verdict that made headlines.
Major Alzheimer’s organisations and dementia researchers pushed back hard, arguing the review’s method was misleading because it lumped together a string of failed first-generation antibodies with the two newer agents that actually work. Averaging the successes in with the failures, they said, washes out a real effect. The disagreement is a reminder that even with two approved drugs, the field is still arguing about how much difference amyloid removal truly makes – and that patients deserve a frank account of modest benefits, not hype.
The Safety Question
The drugs also carry a signature risk known as ARIA, or amyloid-related imaging abnormalities: swelling or small bleeds in the brain that usually show up on scans, often without symptoms, but that can occasionally be serious. Managing it means regular MRI monitoring during treatment.
Risk is not evenly spread. People who carry the APOE e4 gene, especially those with two copies, face a higher chance of ARIA, which is why genetic testing is now recommended before starting therapy so patients can weigh the odds. The subcutaneous form itself did not change that underlying profile; in studies its safety looked similar to the intravenous version, with the most common added issue being mild-to-moderate reactions at the injection site.
The Parallel Revolution: Diagnosing by Blood
While treatment grabs the headlines, an arguably bigger change is happening in diagnosis. New blood tests that measure a marker called p-tau217 can now flag the likely presence of Alzheimer’s amyloid with an accuracy that once required a PET scan or a spinal tap. A positive result still needs confirmation, but as a first-line screen it is transformative.
Because these anti-amyloid drugs only work in early, amyloid-confirmed disease, cheap and simple detection is the gatekeeper to the whole approach. A blood test that a primary-care doctor can order widens the funnel of people who can be identified early enough to be treated – making the convenience of an at-home injection meaningful only if diagnosis keeps pace.
What Comes Next
Leqembi IQLIK for starting treatment is expected to reach US patients in late August 2026. Beyond that, trials are already testing whether treating people even earlier – before symptoms appear, in those who merely carry elevated amyloid – can prevent or delay the disease rather than just slow it once it has taken hold.
For now, the honest summary is measured optimism. Alzheimer’s is, for the first time, treatable rather than untreatable, and the tools are becoming easier to use – a home injection here, a blood test there. But the drugs are modest, monitored and not for everyone, and the arguments about their value are far from settled. The significance of this approval is less a leap in efficacy than a lowering of the barrier to trying at all – which, for families weighing every option, is its own kind of progress.
